AA
CORT icon

AlphaCentric Advisors’s Corcept Therapeutics CORT Stock Holding History

AlphaCentric Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-85,000
Closed -$2.14M – 227
2024
Q1 		$2.14M Buy
+85,000
New +$2.01M 1.29% 21

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

AlphaCentric Advisors's CORT Position: Q2 2024 in Review

AlphaCentric Advisors sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 85,000 shares — an estimated $2.14M sold.

AlphaCentric Advisors first reported a position in CORT in Q1 2024 and held it in 1 quarter. The position peaked at $2.14M in Q1 2024. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • AlphaCentric Advisors reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 85,000 Corcept Therapeutics shares in Q2 2024, an estimated $2.14M.
  • AlphaCentric Advisors first reported a position in Corcept Therapeutics in Q1 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's Corcept Therapeutics position peaked at $2.14M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.